Wenhan Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenhan Peng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Jianghua Chen
Kidney Disease Center, the First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
4 shared publicationsJianyong Wu
Kidney Disease Center, the First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
4 shared publicationsJunhao Lv
Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publicationsYedong Yu
Kidney Disease Center, the First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
3 shared publicationsJunhao Lyu
Kidney Disease Center, the First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
2 shared publicationsLiangping Wang
Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 133 (C) , 111520
Long-term outcomes of kidney transplantation in two recipients from a single membranous nephropathy donor: Case reports and literature review
Introduction and importance: Kidney transplantation encounters a significant challenge due to the persistent shortage of donor organs. Membranous nephropathy (MN) is a rare entity among donor-derived glomerular diseases, and its impact on allograft function and long-term survival remains incompletely understood. Case presentation: We report two kidney transplants from a donor with early-stage MN. The left kidney recipient developed significant proteinuria and elevated creatinine, with a biopsy confirming acute T cell-mediated rejection and donor-derived MN. Following short-term peritoneal dialysis and intensified immunosuppression, serum creatinine levels progressively declined, leading to a restoration of renal function. The right kidney recipient experienced an uncomplicated postoperative course and maintained stable renal function. 8-month protocol biopsies in both recipients demonstrated partial pathological remission. At the 8-year follow-up post-transplantation, both recipients maintained excellent renal function. Clinical discussion: Despite the potential risks of proteinuria and dysfunction, and challenges in donor diagnosis associated with MN donor kidneys, our two cases demonstrate excellent long-term graft function (8-year follow-up), even in one recipient who experienced acute rejection that responded to intensified immunosuppression. These observations suggest the potential for carefully selected MN donor kidneys to expand the donor pool, though larger-scale studies are essential given the limitations of a case report. Conclusion: In these two cases, kidney transplantations from early-stage MN donors exhibited excellent long-term graft function and partial pathological remission. Such results suggest a potential viable strategy to expand the donor pool, contingent upon rigorous clinical oversight and tailored management strategies. Highlights:
- 1 August 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 133 (C) , 111520
Open AccessLong-term outcomes of kidney transplantation in two recipients from a single membranous nephropathy donor: Case reports and literature review
Introduction and importance: Kidney transplantation encounters a significant challenge due to the persistent shortage of donor organs. Membranous nephropathy (MN) is a rare entity among donor-derived glomerular diseases, and its impact on allograft function and long-term survival remains incompletely understood. Case presentation: We report two kidney transplants from a donor with early-stage MN. The left kidney recipient developed significant proteinuria and elevated creatinine, with a biopsy confirming acute T cell-mediated rejection and donor-derived MN. Following short-term peritoneal dialysis and intensified immunosuppression, serum creatinine levels progressively declined, leading to a restoration of renal function. The right kidney recipient experienced an uncomplicated postoperative course and maintained stable renal function. 8-month protocol biopsies in both recipients demonstrated partial pathological remission. At the 8-year follow-up post-transplantation, both recipients maintained excellent renal function. Clinical discussion: Despite the potential risks of proteinuria and dysfunction, and challenges in donor diagnosis associated with MN donor kidneys, our two cases demonstrate excellent long-term graft function (8-year follow-up), even in one recipient who experienced acute rejection that responded to intensified immunosuppression. These observations suggest the potential for carefully selected MN donor kidneys to expand the donor pool, though larger-scale studies are essential given the limitations of a case report. Conclusion: In these two cases, kidney transplantations from early-stage MN donors exhibited excellent long-term graft function and partial pathological remission. Such results suggest a potential viable strategy to expand the donor pool, contingent upon rigorous clinical oversight and tailored management strategies. Highlights:
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 2299-2306
Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy
Background: The administration of trimethoprim-sulfamethoxazole (TMP-SMX) for the prophylaxis of Pneumocystis jirovecii pneumonia (PJP) has proven to be highly efficacious in individuals who have undergone kidney transplantation. Nevertheless, the potential for severe adverse reactions associated with this treatment cannot be overlooked, and the determination of an optimal dosage regimen continues to be a matter of investigation. The current study evaluated the effectiveness of low-dose TMP-SMX for PJP prophylaxis in kidney transplant patients and conducted an analysis of the clinical characteristics and epidemiological trends in patients with PJP infection. Methods: This retrospective analysis studied electronic medical records of 1763 kidney transplant recipients from 2017 to 2020. These patients were initially prescribed a daily half-strength TMP-SMX (40 mg/200 mg), and the efficacy of this regimen was assessed during a follow-up period of 3– 51 months. Results: Under our PJP prevention and adjustment strategy, 24 patients were infected with PJP. The overall morbidity of PJP infection in our study was 1.36%, corroborates with findings from previously published studies. Among these 24 patients, up to 87.5% had their dosage adjusted due to increased creatinine or other adverse reactions, the most frequent dose was daily quarter-strength TMP-SMX (20 mg/100 mg). TMP-SMX prophylaxis successfully postponed and distributed the onset of PJP, with the mean duration from transplantation to the occurrence of PJP being 13.50± 7.11 months. Conclusion: Daily administration of half-strength TMP-SMX can effectively prevent PJP, and prolonging prophylaxis with this medication may potentially reduce the incidence of infection.
- 1 June 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 2299-2306
Open AccessClinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy
Background: The administration of trimethoprim-sulfamethoxazole (TMP-SMX) for the prophylaxis of Pneumocystis jirovecii pneumonia (PJP) has proven to be highly efficacious in individuals who have undergone kidney transplantation. Nevertheless, the potential for severe adverse reactions associated with this treatment cannot be overlooked, and the determination of an optimal dosage regimen continues to be a matter of investigation. The current study evaluated the effectiveness of low-dose TMP-SMX for PJP prophylaxis in kidney transplant patients and conducted an analysis of the clinical characteristics and epidemiological trends in patients with PJP infection. Methods: This retrospective analysis studied electronic medical records of 1763 kidney transplant recipients from 2017 to 2020. These patients were initially prescribed a daily half-strength TMP-SMX (40 mg/200 mg), and the efficacy of this regimen was assessed during a follow-up period of 3– 51 months. Results: Under our PJP prevention and adjustment strategy, 24 patients were infected with PJP. The overall morbidity of PJP infection in our study was 1.36%, corroborates with findings from previously published studies. Among these 24 patients, up to 87.5% had their dosage adjusted due to increased creatinine or other adverse reactions, the most frequent dose was daily quarter-strength TMP-SMX (20 mg/100 mg). TMP-SMX prophylaxis successfully postponed and distributed the onset of PJP, with the mean duration from transplantation to the occurrence of PJP being 13.50± 7.11 months. Conclusion: Daily administration of half-strength TMP-SMX can effectively prevent PJP, and prolonging prophylaxis with this medication may potentially reduce the incidence of infection.
- Open Access
- 1 November 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (11) , 11859-11867
Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series
Background: To observe the efficacy and safety of roxadustat, an inhibitor of proline hydroxylase, in renal allograft anemia patients. Methods: This prospective study collected the clinical data of renal transplant patients treated with roxadustat for anemia at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University from April to August 2020. The patients were followed up every 2 weeks, and the changes in their hemoglobin index and any adverse reactions were recorded during 10 weeks of treatment. The efficacy of roxadustat for treatment of anemia after kidney transplantation was analyzed by comparing the change and increase in average hemoglobin levels before and after treatment. Rates of treatment response and achievement of the standard hemoglobin level were statistically analyzed. In addition, any potential adverse events and the glomerular filtration rate were recorded for 10 weeks to assess the safety of roxadustat in renal allograft anemia patients. Results: After 10 weeks of roxadustat treatment, the mean hemoglobin level was 10.4±3.9 g/dL, which was significantly higher than at baseline. Over the entire period, treatment was observed to have a therapeutic effect at weeks 2–4, with mean hemoglobin levels increasing as treatment time increased. At the 10-week endpoint, the percentage of patients reaching the standard hemoglobin level and exhibiting a response to treatment was 52.4% and 71.4%, respectively. During the treatment, there was no rejection, and the glomerular filtration rate was stable. Only one person showed symptoms of fatigue, and there were no other obvious adverse reactions reported. Conclusions: Roxadustat significantly improves hemoglobin levels and can be safely used in renal transplant anemia patients.
- 1 November 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (11) , 11859-11867
Open AccessEfficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series
Background: To observe the efficacy and safety of roxadustat, an inhibitor of proline hydroxylase, in renal allograft anemia patients. Methods: This prospective study collected the clinical data of renal transplant patients treated with roxadustat for anemia at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University from April to August 2020. The patients were followed up every 2 weeks, and the changes in their hemoglobin index and any adverse reactions were recorded during 10 weeks of treatment. The efficacy of roxadustat for treatment of anemia after kidney transplantation was analyzed by comparing the change and increase in average hemoglobin levels before and after treatment. Rates of treatment response and achievement of the standard hemoglobin level were statistically analyzed. In addition, any potential adverse events and the glomerular filtration rate were recorded for 10 weeks to assess the safety of roxadustat in renal allograft anemia patients. Results: After 10 weeks of roxadustat treatment, the mean hemoglobin level was 10.4±3.9 g/dL, which was significantly higher than at baseline. Over the entire period, treatment was observed to have a therapeutic effect at weeks 2–4, with mean hemoglobin levels increasing as treatment time increased. At the 10-week endpoint, the percentage of patients reaching the standard hemoglobin level and exhibiting a response to treatment was 52.4% and 71.4%, respectively. During the treatment, there was no rejection, and the glomerular filtration rate was stable. Only one person showed symptoms of fatigue, and there were no other obvious adverse reactions reported. Conclusions: Roxadustat significantly improves hemoglobin levels and can be safely used in renal transplant anemia patients.
- Open Access
- 15 October 2021
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11
Donor-Derived Human Parvovirus B19 Infection in Kidney Transplantation
Background: Donor-derived human parvovirus B19 (B19V) infections are rarely reported. Thus, its incidence in kidney transplantation is still unknown due to lack of surveillance studies. Similarly, whether the donor needs to be routinely screened for B19V and whether the kidneys from those with B19V DNAemia could be accepted also remain unknown.Methods: This retrospective study aims to evaluate the donor-derived B19V infections occurring in 823 living and 1,225 deceased donor kidney transplantations from January 2016 to December 2020. The serum viral load of living donors and their corresponding recipients was evaluated before and after transplantation. Meanwhile, for the deceased donor kidney transplantation, the serum viral load of recipients was only tested after transplantation; if recipients of a deceased donor subsequently developed B19V infection, the serum viral load of recipients and their corresponding donors before transplantation would then be further traced.Results: A total of 15 living donors were B19V DNAemia positive before the donation, of which B19V DNAemia occurred in three corresponding recipients. In deceased donor kidney transplantation, DNAemia occurred simultaneously in 18 recipients and their corresponding nine donors. A progressive decline in hemoglobin and reticulocyte count could be observed in one living donor recipient and other 11 deceased donor recipients, which were all well controlled by treatment eventually.Conclusion: The incidence of donor-derived B19V infection was 0.4% and 1.5% in living and deceased kidney transplantations, respectively. B19V was seemingly unnecessary to be routinely screened for the donor. Moreover, kidneys of the donors with B19V infection were acceptable.
- 15 October 2021
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11
Open AccessDonor-Derived Human Parvovirus B19 Infection in Kidney Transplantation
Background: Donor-derived human parvovirus B19 (B19V) infections are rarely reported. Thus, its incidence in kidney transplantation is still unknown due to lack of surveillance studies. Similarly, whether the donor needs to be routinely screened for B19V and whether the kidneys from those with B19V DNAemia could be accepted also remain unknown.Methods: This retrospective study aims to evaluate the donor-derived B19V infections occurring in 823 living and 1,225 deceased donor kidney transplantations from January 2016 to December 2020. The serum viral load of living donors and their corresponding recipients was evaluated before and after transplantation. Meanwhile, for the deceased donor kidney transplantation, the serum viral load of recipients was only tested after transplantation; if recipients of a deceased donor subsequently developed B19V infection, the serum viral load of recipients and their corresponding donors before transplantation would then be further traced.Results: A total of 15 living donors were B19V DNAemia positive before the donation, of which B19V DNAemia occurred in three corresponding recipients. In deceased donor kidney transplantation, DNAemia occurred simultaneously in 18 recipients and their corresponding nine donors. A progressive decline in hemoglobin and reticulocyte count could be observed in one living donor recipient and other 11 deceased donor recipients, which were all well controlled by treatment eventually.Conclusion: The incidence of donor-derived B19V infection was 0.4% and 1.5% in living and deceased kidney transplantations, respectively. B19V was seemingly unnecessary to be routinely screened for the donor. Moreover, kidneys of the donors with B19V infection were acceptable.
- Open Access
- 1 July 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 2911-2923
Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration
Background: Parvovirus B19-associated pure red cell aplasia (PVB19-PRCA) is an uncommon but serious complication after kidney transplantation. Currently, intravenous immunoglobulin (IVIG) is preferred as the first-line treatment for PVB19-PRCA, but presents with disadvantages of disease recurrence and expensive cost. In this context, we propose that foscarnet therapy for kidney transplantation recipients (KTR) with PVB19-PRCA may be an alternative scenario. No related study has been reported, and we performed this study to assess the efficacy and safety of foscarnet for PVB19-associated PRCA in KTR. Methods: We conducted a retrospective review of PVB19-PRCA in KTR at our center over 9-year period. The data on therapy and outcomes in all cases treated with foscarnet are detailed records and summarized. Results: Among our 68 patients, PVB19-PRCA was confirmed in 50 based on inclusion/exclusion criteria. All patients presented with refractory anemia and low reticulocyte percentage (< 0.5%), the mean hemoglobin of patients was 79.8± 12.6g/L at the time of PVB19-PRCA was identified. The median serum genome copy number of parvovirus B19 at diagnosis was 9.6 log10 copies per milliliter. A total of 11 patients received foscarnet therapy, of 10 patients responded well to the treatment and maintained no recurrence. But 1 patient had a poor response to foscarnet therapy. Except for this patient, the mean hemoglobin level gradually increased from 68.5± 9.3 g/L to 73.2± 8.8 g/L, and the mean percentage of reticulocytes steadily increased from 0.1± 0.0% to 7.6± 2.9% after foscarnet therapy. The median serum genome copy number of parvovirus B19 decreased from 9.8 log10 to 6.1 log10 copies per milliliter. There was no significant difference (P=0.61, 0.60) in serum creatinine and glomerular filtration rate before and after foscarnet treatment. At the latest follow-up, the mean hemoglobin was 131.5± 12.5 g/L and the hemoglobin correction occurred in all patients. Conclusion: Foscarnet therapy doesn’t seem to be worse than IVIG for PVB19-PRCA in KTR, and it can be an alternative option.
- 1 July 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 2911-2923
Open AccessFoscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration
Background: Parvovirus B19-associated pure red cell aplasia (PVB19-PRCA) is an uncommon but serious complication after kidney transplantation. Currently, intravenous immunoglobulin (IVIG) is preferred as the first-line treatment for PVB19-PRCA, but presents with disadvantages of disease recurrence and expensive cost. In this context, we propose that foscarnet therapy for kidney transplantation recipients (KTR) with PVB19-PRCA may be an alternative scenario. No related study has been reported, and we performed this study to assess the efficacy and safety of foscarnet for PVB19-associated PRCA in KTR. Methods: We conducted a retrospective review of PVB19-PRCA in KTR at our center over 9-year period. The data on therapy and outcomes in all cases treated with foscarnet are detailed records and summarized. Results: Among our 68 patients, PVB19-PRCA was confirmed in 50 based on inclusion/exclusion criteria. All patients presented with refractory anemia and low reticulocyte percentage (< 0.5%), the mean hemoglobin of patients was 79.8± 12.6g/L at the time of PVB19-PRCA was identified. The median serum genome copy number of parvovirus B19 at diagnosis was 9.6 log10 copies per milliliter. A total of 11 patients received foscarnet therapy, of 10 patients responded well to the treatment and maintained no recurrence. But 1 patient had a poor response to foscarnet therapy. Except for this patient, the mean hemoglobin level gradually increased from 68.5± 9.3 g/L to 73.2± 8.8 g/L, and the mean percentage of reticulocytes steadily increased from 0.1± 0.0% to 7.6± 2.9% after foscarnet therapy. The median serum genome copy number of parvovirus B19 decreased from 9.8 log10 to 6.1 log10 copies per milliliter. There was no significant difference (P=0.61, 0.60) in serum creatinine and glomerular filtration rate before and after foscarnet treatment. At the latest follow-up, the mean hemoglobin was 131.5± 12.5 g/L and the hemoglobin correction occurred in all patients. Conclusion: Foscarnet therapy doesn’t seem to be worse than IVIG for PVB19-PRCA in KTR, and it can be an alternative option.
- Open Access
- 9 May 2021
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 26, e931059-e931059-7
Application of Metagenomic Next-Generation Sequencing to Diagnose Pneumocystis jirovecii Pneumonia in Kidney Transplantation Recipients
Application of Metagenomic Next-Generation Sequencing to Diagnose Pneumocystis jirovecii Pneumonia in Kidney Transplantation Recipients - Article abstract #931059
- 9 May 2021
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 26, e931059-e931059-7
Open AccessApplication of Metagenomic Next-Generation Sequencing to Diagnose Pneumocystis jirovecii Pneumonia in Kidney Transplantation Recipients
Application of Metagenomic Next-Generation Sequencing to Diagnose Pneumocystis jirovecii Pneumonia in Kidney Transplantation Recipients - Article abstract #931059
- Open Access
- 30 November 2018
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 43 (6) , 1813-1821
Hemodialysis or Peritoneal Dialysis, Which Is Better for Patients with Delayed Graft Function?
Background/Aims: Hemodialysis (HD) or peritoneal dialysis (PD) is an important renal replacement method in patients with delayed graft function (DGF) after kidney transplantation; however, it is not clear which dialysis modality is superior. This study determined the impact of different dialysis modalities on patients with DGF. Methods: It was a single-center, retrospective and descriptive study. We performed 673 kidney transplants from donors after cardiac death (DCD) between January 2010 and December 2016 at our center and 138 (20.5%) recipients developed DGF after transplantation. We classified the recipients into two groups according to post-transplant dialysis: DGF-HD (n=96) and DGF-PD (n=42). We analyzed the outcomes of the different dialysis modalities 30 days and 1 year post-transplantation. Results: There were no differences in baseline factors between patients with post-transplant HD (n = 96) or PD (n = 42). There were 10 patients with conversion from PD to HD during DGF. The DGF-PD patients had a higher rate of treatment failure than the DGF-HD patients (23.8% vs. 0%, p < 0.001), peritonitis (7.1% vs. 0%, p = 0.027), and longer duration of dialysis dependence (10.5 vs. 9 days, p = 0.003). There was no statistically significant difference between both groups with respect to acute rejection, hemorrhage, and patient and graft survival at 1 year. Conclusion: In renal transplant recipients with DGF, post-transplant PD led to increased treatment failure. PD did not result in rapid recovery of transplanted renal function, and had a high probability of peritonitis.
- 30 November 2018
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 43 (6) , 1813-1821
Open AccessHemodialysis or Peritoneal Dialysis, Which Is Better for Patients with Delayed Graft Function?
Background/Aims: Hemodialysis (HD) or peritoneal dialysis (PD) is an important renal replacement method in patients with delayed graft function (DGF) after kidney transplantation; however, it is not clear which dialysis modality is superior. This study determined the impact of different dialysis modalities on patients with DGF. Methods: It was a single-center, retrospective and descriptive study. We performed 673 kidney transplants from donors after cardiac death (DCD) between January 2010 and December 2016 at our center and 138 (20.5%) recipients developed DGF after transplantation. We classified the recipients into two groups according to post-transplant dialysis: DGF-HD (n=96) and DGF-PD (n=42). We analyzed the outcomes of the different dialysis modalities 30 days and 1 year post-transplantation. Results: There were no differences in baseline factors between patients with post-transplant HD (n = 96) or PD (n = 42). There were 10 patients with conversion from PD to HD during DGF. The DGF-PD patients had a higher rate of treatment failure than the DGF-HD patients (23.8% vs. 0%, p < 0.001), peritonitis (7.1% vs. 0%, p = 0.027), and longer duration of dialysis dependence (10.5 vs. 9 days, p = 0.003). There was no statistically significant difference between both groups with respect to acute rejection, hemorrhage, and patient and graft survival at 1 year. Conclusion: In renal transplant recipients with DGF, post-transplant PD led to increased treatment failure. PD did not result in rapid recovery of transplanted renal function, and had a high probability of peritonitis.